Survodutide — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 4 sources[1,2,3,4].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind… | The Lancet Diabetes & Endocrinology | 2024 |
| 2 | A phase 2 randomized trial of survodutide in MASH and fibrosis | New England Journal of Medicine | 2024 |
| 3 | Glucagon-like peptide 1 (GLP-1) | Molecular Metabolism | 2019 |
| 4 | Quality of peptide products obtained from unregulated online suppliers: an analytical survey | Journal of Pharmaceutical Sciences | 2024 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 18 | SURVO-PH2-OBESITY · SURVO-PH2-MASH · SYNCHRONIZE-1 · SYNCHRONIZE-2 · SYNCHRONIZE-CVOT · SYNCHRONIZE-1-ELDERLY · SYNCHRONIZE-2-REGIONAL-JP · SYNCHRONIZE-CVOT-RENAL-IMP · SURVO-PH2-OBESITY-ELDERLY · SURVO-PH2-MASH-PK · SYNCHRONIZE-1-OLE · SYNCHRONIZE-CVOT-PK · SURVO-PH2-OBESITY-OLE · SURVO-PH2-MASH-RENAL-IMP and 4 more |
| Evidence syntheses | 5 | Dual and triple incretin receptor agonists compared with… · Incretin receptor agonists for metabolic… · Survodutide in obesity and overweight in adults: effect on… · Survodutide in obesity and overweight in adults… · Survodutide in obesity and overweight in adults: durability… |
| Comment periods | 1 | Draft monograph: Survodutide |
| Indication assessments | 3 | Obesity · MASH · Type 2 diabetes |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology 2024;12(3):162–173. doi:10.1016/S2213-8587(23)00356-X · PMID 38330977
- Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM. A phase 2 randomized trial of survodutide in MASH and fibrosis. New England Journal of Medicine 2024;391(4):311–319. doi:10.1056/NEJMoa2401755 · PMID 38847460
- Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 2019;30:72–130. doi:10.1016/j.molmet.2019.09.010 · PMID 31767182
- Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. doi:10.1016/j.xphs.2023.11.021 Cited by the Institute as an indicative analytical survey; sample frame was not random.
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.